NCT03901378 - Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma | Biotech Hunter

Timeline

Start Date

October 2, 2019

Primary Completion Date

January 21, 2021

Study Completion Date

January 21, 2021

Conditions

Neuroendocrine CarcinomaLarge Cell Neuroendocrine Carcinoma of the LungHigh Grade Neuroendocrine Carcinoma, Any Site

Interventions

DRUG

Pembrolizumab

Intravenous administration of pembrolizumab in combination with cisplatin or carboplatin and etoposide in first line metastatic or unresectable high grade neuroendocrine carcinoma:

Trial Locations (2)

70065

Ochsner Clinic Foundation, Kenner

70121

Ochsner Clinic Foundation, New Orleans